- Home
- MPB vs EYPT Comparison
MPB vs EYPT Comparison
Compare MPB & EYPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MPB
- EYPT
- Stock Information
- Founded
- MPB 1868
- EYPT 1987
- Country
- MPB United States
- EYPT United States
- Employees
- MPB N/A
- EYPT N/A
- Industry
- MPB Major Banks
- EYPT Biotechnology: Laboratory Analytical Instruments
- Sector
- MPB Finance
- EYPT Industrials
- Exchange
- MPB Nasdaq
- EYPT Nasdaq
- Market Cap
- MPB 525.0M
- EYPT 489.4M
- IPO Year
- MPB N/A
- EYPT 2005
- Fundamental
- Price
- MPB $29.19
- EYPT $7.69
- Analyst Decision
- MPB Buy
- EYPT Strong Buy
- Analyst Count
- MPB 2
- EYPT 8
- Target Price
- MPB $36.00
- EYPT $25.71
- AVG Volume (30 Days)
- MPB 71.0K
- EYPT 665.0K
- Earning Date
- MPB 01-22-2025
- EYPT 03-06-2025
- Dividend Yield
- MPB 2.74%
- EYPT N/A
- EPS Growth
- MPB 14.41
- EYPT N/A
- EPS
- MPB 2.91
- EYPT N/A
- Revenue
- MPB $173,416,000.00
- EYPT $45,713,000.00
- Revenue This Year
- MPB N/A
- EYPT N/A
- Revenue Next Year
- MPB $19.26
- EYPT N/A
- P/E Ratio
- MPB $10.05
- EYPT N/A
- Revenue Growth
- MPB 4.93
- EYPT 7.50
- 52 Week Low
- MPB $19.20
- EYPT $6.90
- 52 Week High
- MPB $33.87
- EYPT $30.99
- Technical
- Relative Strength Index (RSI)
- MPB 46.67
- EYPT 41.66
- Support Level
- MPB $30.02
- EYPT $7.58
- Resistance Level
- MPB $31.36
- EYPT $8.16
- Average True Range (ATR)
- MPB 0.75
- EYPT 0.55
- MACD
- MPB 0.16
- EYPT -0.07
- Stochastic Oscillator
- MPB 45.23
- EYPT 3.06
About MPB Mid Penn Bancorp
Mid Penn Bancorp Inc operates in the financial services domain. It conducts commercial banking and trust business in the United States. Its range of services comprises mortgage and home equity loans, secured and unsecured consists and consumer loans, lines of credit, construction financing, farm loans, community development, local government loans, and various types of time and demand deposits.
About EYPT EyePoint Pharmaceuticals Inc.
EyePoint Pharmaceuticals Inc is a pharmaceutical company. It is engaged in developing and commercializing ophthalmic products for the treatment of eye diseases. The company has developed FDA-approved sustained-release treatments in ophthalmology. Its pre-clinical development program is focused on using its core Durasert E and Verisome technology platforms to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis, and other diseases. Geographically, the firm has operational footprints in the U.S., China, and the UK. It generates a majority of its revenue from the U.S.